Navigation Links
Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting

CAMBRIDGE, Mass., April 18, 2007 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases, announced today that 11 abstracts have been accepted for presentation at the 2007 Digestive Disease Week (DDW) meeting, to be held in Washington D.C. from May 19 to 24. The abstract contents are available on the DDW web site at http://www.ddw.org .

Hepatitis C Abstracts:

Dr. Norman Gitlin, Professor of Medicine, Atlanta Gastroenterology Associations and Emory University, Atlanta, GA, will present "Valopicitabine (NM283) Plus Peg-Interferon Alfa-2a (peg-IFN) in Treatment-Naive Patients With HCV-1 Infection: Preliminary Results At Weeks 24 and 48" in a poster session beginning on Monday, May 21, 2007 at 8:00 a.m. Eastern Daylight Time (EDT).

Dr. Maribel Rodriguez-Torres, President, Fundacion de Investigacion de Diego, Santurce, Puerto Rico, will present "Final Results from a Phase IIA Pharmacokinetic Study of Valopicitabine (NM283) and Peg-IFNa-2b in Patients with Genotype 1 Chronic Hepatitis C" in a poster session beginning on Monday, May 21, 2007 at 8:00 a.m. EDT.

About Valopicitabine (NM283)

Valopicitabine is an investigational HCV RNA polymerase inhibitor being evaluated in ongoing clinical trials for the treatment of hepatitis C.

Hepatitis B Abstracts

Dr. Maria Seifer, Director, Biology at Idenix Pharmaceuticals, will present "Genotypic Analysis of Patients with Evaluable HBV DNA After 1 Year of Telbivudine Therapy in the GLOBE Registration Trial" in a meeting session on Sunday, May 20, 2007 at 11:15 a.m. EDT.

Dr. Steven Han, Associate Clinical Professor in the Division of Digestive Diseases and the Division of Liver and Pancreas Transplantation and Directo
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/22/2014)... YORK , September 22, 2014 ... Market Report on "Global Market Study on Ophthalmic Devices: ... by 2020," the global ophthalmic devices market was valued at USD ... at a CAGR of 6.5% from 2014 to 2020, ... in 2020. Browse the full Global Market Study ...
(Date:9/22/2014)... VICTORIA, BC , Sept. 22, 2014 /CNW/ - ... pharmaceutical company focused on developing premium quality medical marijuana ... subsidiary, Thunderbird Biomedical Inc. ("Thunderbird"), has signed a definitive ... Victoria , BC.  The facility has 28,966 ... add approximately 14,500 square feet of mezzanine space for ...
(Date:9/22/2014)... MEETING, Pa. , Sept. 22, 2014 /PRNewswire/ ... announced today it has initiated a phase I ... trial will evaluate the safety, tolerability, and immunogenicity ... 6 (HPV-6), which causes most aerodigestive cancers. ... nose, throat, vocal cords, and parts of the ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... Dec. 7, 2010 Royal Philips Electronics (NYSE: PHG, ... of an international analysis on issues and challenges facing ... a greater reliance on home healthcare is necessary to ... growing aging population living longer with chronic illnesses. ...
... /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" or "the Company"), ... manufacturer and distributor of probiotics products in China, ... research and development department presented at the National ... seminar in Hangzhou, China on November 21st. ...
Cached Medicine Technology:Philips-Commissioned RAND Report Highlights Promise of Home Health and Need for Multi-Stakeholder Action to Break Down Barriers to Adoption 2Philips-Commissioned RAND Report Highlights Promise of Home Health and Need for Multi-Stakeholder Action to Break Down Barriers to Adoption 3China-Biotics Attended National Probiotics Seminar 2China-Biotics Attended National Probiotics Seminar 3
(Date:9/22/2014)... 22, 2014) McMaster scientists have found that an ... of antibiotics. , Although dozens of antibiotics target ... a certain part of bacteria are created, and they ... , The discovery is important as there is growing ... cures for infections ineffective. The World Health Organization has ...
(Date:9/22/2014)... 2014 Quincy Bioscience, one of ... promotes National Self-Improvement Month this September. ... should have access to self-improvement resources, especially for ... demand for products that preserve health is growing ... For over six years, Quincy Bioscience has been ...
(Date:9/22/2014)... (HealthDay News) -- Scans of young children,s brains ... This finding could potentially allow doctors to identify ... on, preliminary research suggests. "Early identification and ... as well as most neurodevelopmental disorders," the study,s ... of child and adolescent psychiatry at University of ...
(Date:9/22/2014)... September 22, 2014 In a continued ... Jeep Dodge Ram is launching an awareness campaign inspired ... (#blindeggchallenge or #ffbBEC) aims to raise awareness and funds ... throwing an egg in the air and trying to ... others and if a nominee does not complete the ...
(Date:9/22/2014)... 22, 2014 The struggles that lie ... (LEP) patients has been well-documented—reportedly, language barriers between doctors ... to the emergency room and an increased likelihood for ... At Sanford Health, the largest medical facility in the ... LEP population necessitated the need for Video Remote ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 3Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 4
... Corporation,s (Nasdaq: CRVL ) quarterly earnings release, CorVel will be conducting a ... 11:30 am Eastern Time. , , Event: ... Dan Starck, President and CEO, ... 11:30 am Eastern Time, Tuesday, February 3rd, ...
... success rate is much lower for those over 40 who want ... Women under 35 who undergo six cycles of in vitro fertilization ... new study found. , But for women over 40, the odds ... , "IVF is a mainstay of the treatment of infertility, and ...
... 14 ISP and IT partner Spiderhost ... initiative by Get Healthy Florida to get ... most comprehensive community-wide health project to date: a year-long ... awareness of blood pressure and cardiovascular risk.The project challenges ...
... 14 Congressman Chaka Fattah (D-PA) issues the ... the SCHIP children,s insurance program by a bipartisan vote of ... , "The effort to bring change to Washington ... children took a major stride today. I have joined with ...
... RIVER EDGE, N.J., Jan. 14 Nephros, Inc. ... company developing and marketing filtration products for therapeutic ... that it has received notice from the NYSE ... or "AMEX" or the "Exchange"), regarding AMEX,s intention ...
... still share outcome disparities in treatment of liver disease, study ... treatment for hepatitis C does not appear to help Hispanic ... non-Hispanic whites, a new study suggests. , This is second ... not to respond well to the therapy, consisting of pegylated ...
Cached Medicine News:Health News:CorVel Corporation Announces Earnings Release Webcast 2Health News:IVF Treatments Often Work for Women Under 35 2Health News:IVF Treatments Often Work for Women Under 35 3Health News:Spiderhost's Custom Programming Helps Central Floridians Get Healthy 2Health News:Nephros Receives Notice of Intention to Delist from AMEX 2Health News:Nephros Receives Notice of Intention to Delist from AMEX 3Health News:Nephros Receives Notice of Intention to Delist from AMEX 4Health News:Hispanics Respond Poorly to Standard Hepatitis C Therapy 2
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
... BTF-111 miniature arrayed detector ... spectrometer for ?uorescence applications ... excitation light source modules ... 2D ?uorescence measurement which ...
Inquire...
FlexStationII offers the highest level of flexibility in developing functional cellular assays and analyzing real time kinetic data....
Medicine Products: